| Stage | CPAY | % of rev | RXO | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.3B | 100.00% | $1.9B | 100.00% | RXO ×1.40 |
| Gross profit | $1.1B | 79.45% | $333M | 17.80% | CPAY +61.6pp |
| Operating income | $472M | 35.28% | $17M | 0.91% | CPAY +34.4pp |
| Pre-tax income | $345M | 25.75% | $6M | 0.32% | CPAY +25.4pp |
| Net income | $252M | 18.81% | $3M | 0.16% | CPAY +18.6pp |
| Stage | CPAY | RXO | Gap · A − B |
|---|---|---|---|
| Revenue | $1.3B100.00% | $1.9B100.00% | RXO ×1.40 |
| Gross profit | 79.45%$1.1B | 17.80%$333M | CPAY +61.6pp |
| Operating income | 35.28%$472M | 0.91%$17M | CPAY +34.4pp |
| Pre-tax income | 25.75%$345M | 0.32%$6M | CPAY +25.4pp |
| Net income |
| 18.81%$252M |
| 0.16%$3M |
| CPAY +18.6pp |
No shared counterparties.